Cholangitis Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: May 03, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
3.8% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Disease Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global cholangitis diagnostics market is expected to register a revenue CAGR of 3.8% in the forecast period from 2023 to 2031.
Cholangitis Diagnostics Market Fundamentals
Cholangitis is characterized by inflammation of the bile ducts, which carry bile from the liver to the gallbladder and small intestine. A combination of medical history, physical examination, and other diagnostic procedures are used to diagnose cholangitis. Blood tests to evaluate the liver's function and search for infection indicators are one of the most important diagnostic procedures for cholangitis. Cholangitis can be detected by elevated levels of specific liver enzymes like alkaline phosphatase and bilirubin and a raised white blood cell count. Diagnostic imaging procedures like ultrasonography, magnetic resonance cholangiopancreatography (MRCP), and endoscopic retrograde cholangiopancreatography (ERCP) are frequently used to identify cholangitis. These examinations can assist in establishing the presence of obstructions or other abnormalities in the bile ducts and the severity of the illness. To confirm the diagnosis and determine the underlying cause of the cholangitis, a tissue sample (biopsy) from the liver or bile ducts may occasionally be removed.
Cholangitis can be more accurately, quickly, and conveniently diagnosed with recent advancements in diagnostic technology, resulting in early treatment and better patient outcomes. One such breakthrough is introducing sophisticated imaging methods that enable non-invasive visualization of the bile ducts. Additionally, improvements in laboratory testing have produced more accurate and focused biomarkers for cholangitis, including elevated levels of bilirubin and alkaline phosphatase.
Cholangitis Diagnostics Market Dynamics
Globally, the prevalence of cholangitis is rising due to factors like rising rates of obesity, diabetes, and other liver disease risk factors. As a result, there is an increasing need for cholangitis diagnostic tests and therapies. According to estimates, 1-3 instances of acute cholangitis per 100,000 people in the United States per year. In contrast, the prevalence of cholangitis varies by nation but is generally between 0.5 and 3.1 cases per 100,000 people per year. In addition, the incidence of cholangitis appears to be increasing, possibly due to the rising prevalence of risk factors such as obesity and diabetes. Also, the rising prevalence of gallstones, biliary tract infections, and autoimmune diseases is contributing to the growth of the cholangitis diagnostics market. Therefore, the upsurge in the prevalence of the disease supports the cholangitis diagnostics industry trends toward introducing improved cutting-edge cholangitis diagnostic methods in the market.
In recent years, the accuracy of detecting cholangitis has increased through improvements in imaging techniques like MRCP and endoscopic ultrasound (EUS). High-resolution pictures of the bile ducts can be obtained using EUS and can also be used to collect tissue samples for biopsies. Additionally, analyzing blood, urine, or other bodily fluids for the presence of particular biomarkers can point to the existence of cholangitis. For instance, high blood levels of some proteins, such as procalcitonin and C-reactive protein (CRP), can signal inflammation and infection. Furthermore, artificial intelligence (AI) algorithms can analyze medical images and help radiologists identify abnormalities in the bile ducts. The speed and accuracy of diagnosis may both benefit from this. Additionally, AI can support the identification of diseases in their early stages that may not be visible to the human eye, enabling earlier treatment and improved patient outcomes. The evolvement of innovative technology with enhanced research and development influences the cholangitis diagnostics market dynamics regarding revenue generation.
More people are seeking medical attention for liver-related illnesses, including cholangitis, due to increased public awareness of the significance of liver health. Additionally, the cholangitis diagnostics market is seeing new growth opportunities due to the development of healthcare infrastructure in emerging economies and the rise in global healthcare expenditure. The rising demand for point-of-care testing also influences the cholangitis diagnostics market dynamics because it provides quicker findings and can be done in places like hospitals, clinics, and even at home.
However, cholangitis is rare; many medical professionals might be unaware of its diagnosis and care. Delay or erroneous diagnoses may result from this, affecting patient outcomes. Furthermore, access to the latest diagnostic techniques like MRI and EUS may be restricted in some areas. This can make it challenging to diagnose cholangitis and other liver conditions precisely. In addition, the high procedure cost and complications in the methods restrict the cholangitis diagnostics market growth.
Cholangitis Diagnostics Market Ecosystem
The global cholangitis diagnostics market overview is analyzed from the following perspectives: type, disease type, end user, and region.
Cholangitis Diagnostics Market by Type
[10]
Based on the types, the global cholangitis diagnostics market is segmented into imaging tests and molecular diagnostic tests. The imaging test is sub-segmented into magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, and fibro scan. The molecular diagnostics tests are also sub-segmented into blood tests, cholesterol tests, liver tests, and others.
Imaging tests accounted for the largest revenue share of the global cholangitis diagnostics market in 2022. A detailed image of the biliary tract can be obtained using imaging tests like ultrasound, CT scan, and MRI, which can help detect blockages or other abnormalities. These tests are frequently employed as the first line of diagnostic tests for cholangitis. As a result, the global market for cholangitis diagnostics has seen the biggest revenue share from imaging tests.Most healthcare facilities, including hospitals, clinics, and imaging centers, offer various imaging tests, making them readily available to patients. Additionally, imaging tests can help locate the spot and severity of blockages or other abnormalities in the biliary tract and are typically trustworthy and accurate.
Nevertheless, improvements in molecular diagnostics have resulted in the creation of brand-new tests that can identify particular biomarkers connected to cholangitis. The molecular diagnostics for cholangitis diagnostics are anticipated to expand due to these tests' improved sensitivity and specificity compared to imaging techniques.
Cholangitis Diagnostics Market by Disease Type
Based on the disease type, the global cholangitis diagnostics market is segmented into acute cholangitis, primary sclerosing cholangitis, secondary sclerosing cholangitis, and recurrent pyogenic.
Acute cholangitis accounted for the largest revenue share of the global cholangitis diagnostics market in 2022. The increasing prevalence of acute cholangitis is the most important driving factor for the advanced diagnostic procedure shaping the cholangitis diagnostics market size. In 2023, according to the National Institute of Health information, acute cholangitis is estimated to be between 1-3 cases per 100,000 people per year. The incidence of primary sclerosing cholangitis (PSC), a chronic form of cholangitis, is estimated to be around 1.3 cases per 100,000 people per year. Acute cholangitis requires urgent treatment with antibiotics, endoscopic or surgical treatments to remove the obstruction in the bile ducts and other supportive measures. Thus a precise diagnosis is essential. As a result, a significant demand for reliable and accurate diagnostic tests drives up sales in the cholangitis diagnostics market growth.
Cholangitis Diagnostics Market by End User
based on the end user, the global cholangitis diagnostics market is segmented into hospitals and specialty clinics, ambulatory surgery centers, and diagnostic centers.
The hospitals and specialty clinics accounted for the highest revenue share of the global cholangitis diagnostics market in 2022. To diagnose and treat complex diseases like cholangitis, hospitals, and clinics often have a wide range of diagnostic resources, including imaging tools, laboratory testing, and other specialist equipment. Hospitals and clinics often have access to specialists like gastroenterologists, hepatologists, and interventional radiologists who can accurately diagnose and treat cholangitis. Hospitals and clinics often see more patients than other healthcare settings, which might lead to more frequent cholangitis and other liver illnesses diagnoses. Moreover, health insurance policies generally pay for imaging, laboratory testing, and other diagnostic procedures for cholangitis performed in hospitals. Hospitals and clinics may be better able to manage the insurance reimbursement process since they frequently have established ties with insurance providers.
Cholangitis Diagnostics Market by Region
Based on the region, the global cholangitis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global cholangitis diagnostics market in 2022. The area boasts a strong network of hospitals, clinics, and diagnostic facilities equipped with cutting-edge imaging and laboratory technology to diagnose and treat cholangitis. Additionally, North America has a high prevalence of conditions that increase the risk of developing cholangitis, including obesity, diabetes, and gallstones. These conditions have helped to explain the region's high incidence of cholangitis cases. The region's market growth has also been aided by the rising demand for sophisticated diagnostic methods and the expanding use of cutting-edge technologies like molecular testing and imaging powered by artificial intelligence. The region's dominance in the cholangitis diagnostics market is also due to significant companies and attractive reimbursement policies for cholangitis diagnostic procedures.
According to the cholangitis diagnostics industry analysis, the Asia Pacific region is considered the fastest-growing market with a rapid increase in revenue CAGR. Cholangitis risk factors include viral hepatitis, and liver cirrhosis are very common in the area. Additionally, the region's market has grown due to the rising demand for sophisticated diagnostic methods and the expanding use of revolutionary technologies like point-of-care testing and next-generation sequencing. The cholangitis diagnostics market in the Asia Pacific region has grown due to affordable diagnostic techniques, growing investments in healthcare infrastructure, and rising disposable income.
Cholangitis Diagnostics Market Competitive Landscape
Multiple companies across the globe are investing in raising awareness and reimbursement, which is expected to improve the cholangitis diagnostics market outlook. Notable market participants account for the largest revenue share of the global cholangitis diagnostics market, including,
Cholangitis Diagnostics Market Strategic Developments
Cholangitis diagnostics refers to the range of medical procedures and tests used to detect and diagnose cholangitis, a potentially life-threatening infection of the bile ducts.
Imaging tests accounted for the largest revenue share of the global cholangitis diagnostics market.
Increased health awareness and advancement in R&D for developing innovative diagnostic devices are the major drivers for the cholangitis diagnostics market.
Key companies operating the global cholangitis diagnostics market are Bayer AG, Taiho Pharmaceutical Co. Ltd., Gilead Sciences, RIEMSER Pharma GmbH, Zambon Company S.P.A., and NGM Biopharmaceuticals.
The global cholangitis diagnostics market is expected to grow at a revenue CAGR of 3.8% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain